Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting-Reference-Cited by-同舟云学术

Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting

Published:2015-08 Issue:2 Volume:89 Page:161-166
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Sassier Marion,Dugué Audrey Emmanuelle,Clarisse Bénédicte,Lesueur Paul^ORCID,Avrillon Virginie,Bizieux-Thaminy Acya,Auliac Jean-Bernard,Kaluzinski Laure,Tillon Julie,Robinet Gilles,Le Caer Hervé,Monnet Isabelle,Madroszyk Anne,Boza Gabriella,Falchero Lionel,Fournel Pierre,Egenod Thomas,Toffart Anne-Claire,Leiber Nathalie,Do Pascal,Gervais Radj

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Maintenance therapies for non-small cell lung cancer;Blais;Front Oncol,2014

2. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

3. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil;Reck;J Clin Oncol,2009

4. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study;Ciuleanu;Lancet,2009

5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience;Lung Cancer;2022-12

2. Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab;CEN Case Reports;2021-08-18

3. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges;World Journal of Gastroenterology;2021-07-14

4. Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity;Scientific Reports;2021-01-12

5. Acute tubular necrosis after selective FGFR tyrosine kinase inhibitor therapy;European Journal of Cancer;2020-11